A one-year survey on the use of a powder from rosa canina lito in acute exacerbations of chronic pain

Phytotherapy Research

Volumn 22, Issue 9, 2008, Pages 1141-1148

  Chrubasik, C ^a   Wiesner, L ^a   Black, A ^b   Muller Ladner U ^c   Chrubasik, S ^a,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Long term treatment; Low back pain; Osteoarthritis; Rose hip and seed

Indexed keywords

DICLOFENAC; GALACTOLIPID; LITOZIN; PARACETAMOL; PLANT EXTRACT; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DATA ANALYSIS; DISABILITY; DISEASE EXACERBATION; FEMALE; HARPAGOPHYTUM; HIP; HUMAN; KNEE; LONG TERM CARE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OSTEOARTHRITIC PAIN; PLANT SEED; POWDER; RECOMMENDED DRUG DOSE; ROSA CANINA LITO; ROSE; SAFETY; SYMPTOM; TIME; WELLBEING;

CHRONIC DISEASE; DATA COLLECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS; PAIN; PILOT PROJECTS; POWDERS; ROSA; TREATMENT OUTCOME;

HARPAGOPHYTUM; ROSA CANINA;

EID: 46849122185     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2352     Document Type: Article

References (22)

1. Altman R, Alarcon G, Appelrouth D et al. 1991. The American College of Rheumatology criteria for classification and reporting of osteoarthritis of the hip. Arthritis Rheum 34: 505-514.
2. Altman R, Asch E, Bloch D et al. 1986. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 29: 1039-1049.
3. Anonymous. 1998. Rosa canina L. In Hagers Handbuch der Pharmazeutischen Praxis, Bd 3, Blaschek W, Händel R, Keller K, Reichling J, Rimpler H, Schneider G (eds). Springer: Berlin, 447-452.
4. Blumenthal M. 1998. The Complete German Commission E Monographs. The American Botanical Council: Austin, TX, 369.
5. Carey TS, Garrett JM, Jackman AM. 2000. Beyond the good prognosis. Examination of an inception cohort of patients with chronic low back pain. Spine 25: 115-120.
6. Chrubasik C, Duke RK, Chrubasik S. 2006. The evidence for clinical efficacy of rose hip and seed: a systematic review. Phytother Res 20: 1-3.
7. Chrubasik JE, Roufogalis B, Chrubasik S. 2007b. Systematic review on the safety of Harpagophytum preparations for osteoarthritic or low back pain. Phytother Res 22: 149-152.
8. R. Phytomedicine 14: 371-376.
9. Chrubasik S, Conradt C, Black A. 2003a. The quality of clinical trials with Harpagophytum procumbens. Phytomedicine 10: 613-623.
10. Chrubasik S, Künzel O, Acker A, Conradt C, Kerschbaumer F. 2001. Potential economic impact of using a proprietary willow bark extract in outpatients treatment of low back pain: an open non-randomized study. Phytomedicine 8: 241-251.
11. R for low back pain. Phytomedicine 11: 470-477.
12. Chrubasik S, Model A, Pollak S, Black A. 2003b. A randomised double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology 42: 141-148.
13. R. Phytomedicine 9: 181-194.
14. Costa LCM, Henschke N, Maher CG et al. 2007. Prognosis of chronic low back pain: design of an inception cohort study. BMC Musculoskelet Disord 8: 11.
15. Fordyce WE. 1995. Back Pain in the Workplace: Management of Disability in Nonspecific Conditions. A Report of the Task Force on Pain in the Workplace of the International Association for the Study of Pain.
16. Gagnier JJ, van Tulder MW, Berman B, Bombardier C. 2007. Herbal medicine for low back pain: a Cochrane review. Spine 32: 82-92.
17. Larsen E, Kharazmi A, Christensen LP, Brogger Christensen S. 2003. An anti-inflammatory galactolipid from rose hip (Rosa canina L.) inhibits chemotaxis of human peripheral blood neutrophils in vitro. J Nat Prod 66: 994-995.
18. Pham T, van der Heijde D, Altman RD et al. 2004. OMERACT-OARSI Initiative. Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 12: 389-399.
19. Pham T, Van Der Heijde D, Lassere M et al. 2003. OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 30: 1648-1654.
20. Rein E, Kharazmi A, Winther K. 2004. A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis - a double-blind, placebo-controlled, randomised trial. Phytomedicine 11: 383-391.
21. Warholm O, Skaar S, Hedman E, Molmen HM, Eik L. 2003. The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Curr Ther Res 64: 21-31.
22. Winther K, Rein E, Kharazmi A. 1999. The anti-inflammatory properties of rose-hip. Inflammopharmacology 7: 377-386.